Results 1 to 10 of about 6,725 (159)

Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis

Current Oncology, 2022
Background: Patients with epithelial ovarian cancer (EOC), treated with niraparib maintenance, present with haematological and gastrointestinal toxicities. Limited data exist on niraparib safety assessment. Objective: To evaluate niraparib safety profile,
Ioannis Mamais, Aris P Agouridis, Adamantios Michalinos   +2 more
exaly   +3 more sources

Niraparib Restricts Intraperitoneal Metastases of Ovarian Cancer by Eliciting CD36-Dependent Ferroptosis

Redox Biology
Ovarian cancer (OC) is prone to peritoneum or omentum dissemination, thus giving rise to the formidable challenge of unresectable surgery and a dismal survival rate.
Yu Xia, Ning Jin
exaly   +3 more sources

Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study [PDF]

Frontiers in Oncology
BackgroundPARP(Poly(ADP-ribose) polymerase) inhibitors are established as effective treatment for ovarian cancer; however, there have been no systematic studies of PARP inhibitor use in older patients with ovarian cancer.MethodsThis study was conducted ...
Jingjing Lu, Jingjing Lu, Xuelian Song, Chen Zhang, Yi Zhu, Huarui Yang, Yi Li   +6 more
doaj   +2 more sources

CDK4/6i reverse PARPi resistance by targeting the E2F1- MCM2/5 pathway [PDF]

npj Precision Oncology
Resistance to poly (ADP-ribose) polymerase inhibitors (PARPis) like niraparib represents a major therapeutic challenge in ovarian cancer (OC). This study elucidates a novel resistance mechanism driven by the minichromosome maintenance proteins 2 and 5 ...
Yujie Feng, Miao Fu, Bowen Zheng, Fanzhuoran Lou, Xintian Huang, Xiaowen Xie, Weijuan Tan, Quan Chen, Wenqing Zhang, Yongxiang Hong, Kaiyi Rong, Huibo Shi, Tianhui Hu, Li Xiao   +13 more
doaj   +2 more sources

DYRK1B Inhibition by AZ191 Sensitizes High-Grade Serous Ovarian Cancer to Niraparib Through Promoting Apoptosis and Ferroptosis [PDF]

Biomedicines
Background/Objectives: The clinical challenges of PARP inhibitors in ovarian cancer include the lack of effective maintenance regimens for homologous recombination proficiency (HRP) patients and the emergence of acquired resistance in initially ...
Yu Gao, Yuanyuan Cao, Junyao Liu, Fang Tong, Xianlin Liu, Jiahui Wang, Peixuan Liu, Yanting Xu, Lu Feng, Pengxin Zhang, Jingchun Gao, Jiwei Liu   +11 more
doaj   +2 more sources

Short-term starvation synergistically enhances cytotoxicity of Niraparib via Akt/mTOR signaling pathway in ovarian cancer therapy

Cancer Cell International, 2022
Background Short-term starvation (STS) has gradually been confirmed as a treatment method that synergistically enhances the effect of chemotherapy on malignant tumours.
Wang Zhi, Suting Li, Yuting Wan, Fuwen Wu, Li Hong   +4 more
doaj   +1 more source

Effects of the PARP inhibitor Niraparib on the radiosensitivity of human lung and cervical cancer cells

Radiation Medicine and Protection, 2023
Objective: To investigate the effect of Niraparib, a clinically approved PARP inhibitor on the radiosensitivity of human lung and cervical cancer cells, and preliminarily explore the underlying mechanism. Methods: The human lung cancer cell line A549 and
Yue Feng, Shiyi Pi, Yuwei Li, Yu Zhang, Hongwei Zeng, E. Xiangyu, Yang Zhang, Jingping Yu   +7 more
doaj   +1 more source

Efficacy of oral ferric citrate hydrate treatment for anemia caused by niraparib: a case report

Journal of Medical Case Reports, 2022
Background Maintenance therapy using poly(adenosine diphosphate-ribose)polymerase inhibitors may have adverse events, including hematological toxicity, and may limit therapeutic potential in patients with cancer.
Hiroshi Kobayashi, Yuki Yamada
doaj   +1 more source

Niraparib-induced STAT3 inhibition increases its antitumor effects

Frontiers in Oncology, 2022
Recently, poly(ADP-ribosyl)ation polymerase inhibitors (PARPis), which induce synthetic lethality of tumor cells with DNA damage repair defects, have emerged as a promising therapy for ovarian, breast, and pancreatic cancer.
Qianqian Zhao, Qianqian Zhao, Adrian Kohut, Yi-Jia Li, Antons Martincuks, Theresa Austria, Chunyan Zhang, Nicole Lugo Santiago, Rosemarie Martinez Borrero, Rosemarie Martinez Borrero, Xuan Thuy Phan, Laleh Melstrom, Lorna Rodriguez-Rodriguez, Hua Yu   +13 more
doaj   +1 more source

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib

Scientific Reports, 2022
Niraparib was approved for the treatment of platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube and primary peritoneal cancer. The authors retrospectively investigated niraparib-related adverse events (AEs) through data mining of the ...
Menglin Guo, Yamin Shu, Guosong Chen, Juan Li, Feie Li   +4 more
doaj   +1 more source